MedTrace Logo

A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

NCT02019940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-04-01

Study results available
· View outcomes & findings →

Summary

This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.

Conditions

Interventions

DRUG

Riluzole

Sponsors & Collaborators

  • National Center for PTSD

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Chadi Abdallah, MD · National Center for PTSD / Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2020-01-31
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02019940 on ClinicalTrials.gov